High Expression of PDGFR-β in Prostate Cancer Stroma is Independently Associated with Clinical and Biochemical Prostate Cancer Recurrence

Overview

Journal Sci Rep

Specialty Science

Date 2017 Feb 25

PMID 28233816

Citations 39

Authors

Yngve Nordby

Elin Richardsen

Mehrdad Rakaee

Nora Ness

Tom Donnem

Hiten R H Patel

Lill-Tove Busund

Roy M Bremnes

Sigve Andersen

Affiliations

Soon will be listed here.

Abstract

Due to a lack of sufficient diagnostic tools to predict aggressive disease, there is a significant overtreatment of patients with prostate cancer. Platelet derived growth factors (PDGFs) and their receptors (PDGFRs) are key regulators of mesenchymal cells in the tumor microenvironment, and has been associated with unfavorable outcome in several other cancers. Herein, we aimed to investigate the prognostic impact of PDGFR-β and its ligands (PDGF-B and PDGF-D) in a multicenter prostatectomy cohort of 535 Norwegian patients. Using tissue microarrays and immunohistochemistry, the expression of ligands PDGF-B and PDGF-D and their corresponding receptor, PDGFR-β, was assessed in neoplastic tissue and tumor-associated stroma. PDGFR-β was expressed in benign and tumor associated stroma, but not in epithelium. High stromal expression of PDGFR-β was independently associated with clinical relapse (HR = 2.17, p = 0.010) and biochemical failure (HR = 1.58, p = 0.002). This large study highlights the prognostic importance of PDGFR-β expression, implicating its involvement in prostate cancer progression even in early stage disease. Hence, analyses of PDGFR-β may help distinguish which patients will benefit from radical treatment, and since PDGFR-β is associated with relapse and shorter survival, it mandates a focus as a therapeutic target.

Citing Articles

Cancer-associated fibroblasts as therapeutic targets for cancer: advances, challenges, and future prospects.

Cao Z, Quazi S, Arora S, Osellame L, Burvenich I, Janes P J Biomed Sci. 2025; 32(1):7.

PMID: 39780187 PMC: 11715488. DOI: 10.1186/s12929-024-01099-2.

Identifying Key Genes as Progression Indicators of Prostate Cancer with Castration Resistance Based on Dynamic Network Biomarker Algorithm and Weighted Gene Correlation Network Analysis.

Liu S, Hu Y, Liu F, Jiang Y, Wang H, Wu X Biomedicines. 2024; 12(9).

PMID: 39335669 PMC: 11429123. DOI: 10.3390/biomedicines12092157.

Functional and clinical roles of stromal PDGF receptors in tumor biology.

Strell C, Rodriguez-Tomas E, Ostman A Cancer Metastasis Rev. 2024; 43(4):1593-1609.

PMID: 38980580 PMC: 11554757. DOI: 10.1007/s10555-024-10194-7.

Tumor biomarkers for diagnosis, prognosis and targeted therapy.

Zhou Y, Tao L, Qiu J, Xu J, Yang X, Zhang Y Signal Transduct Target Ther. 2024; 9(1):132.

PMID: 38763973 PMC: 11102923. DOI: 10.1038/s41392-024-01823-2.

Antioxidant, Anti-Inflammatory and Antiproliferative Effects of (Thunb.) Lour. Flower Extracts.

Huang S, Bueno P, Garcia P, Lee M, De Castro-Cruz K, Leron R Plants (Basel). 2023; 12(17).

PMID: 37687413 PMC: 10489841. DOI: 10.3390/plants12173168.

References

Bremnes R, Veve R, Gabrielson E, Hirsch F, Baron A, Bemis L . High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. J Clin Oncol. 2002; 20(10):2417-28. DOI: 10.1200/JCO.2002.08.159. View

Singh D, Febbo P, Ross K, Jackson D, Manola J, Ladd C . Gene expression correlates of clinical prostate cancer behavior. Cancer Cell. 2002; 1(2):203-9. DOI: 10.1016/s1535-6108(02)00030-2. View

Najy A, Jung Y, Won J, Conley-LaComb M, Saliganan A, Kim C . Cediranib inhibits both the intraosseous growth of PDGF D-positive prostate cancer cells and the associated bone reaction. Prostate. 2012; 72(12):1328-38. PMC: 3369116. DOI: 10.1002/pros.22481. View

Huang W, Fridman Y, Bonfil R, Ustach C, Conley-LaComb M, Wiesner C . A novel function for platelet-derived growth factor D: induction of osteoclastic differentiation for intraosseous tumor growth. Oncogene. 2011; 31(42):4527-35. PMC: 3482867. DOI: 10.1038/onc.2011.573. View

Bill-Axelson A, Garmo H, Holmberg L, Johansson J, Adami H, Steineck G . Long-term distress after radical prostatectomy versus watchful waiting in prostate cancer: a longitudinal study from the Scandinavian Prostate Cancer Group-4 randomized clinical trial. Eur Urol. 2013; 64(6):920-8. DOI: 10.1016/j.eururo.2013.02.025. View

Mathew P, Tannir N, Tu S, Wen S, Guo C, Marcott V . Accelerated disease progression in prostate cancer and bone metastases with platelet-derived growth factor receptor inhibition: observations with tandutinib. Cancer Chemother Pharmacol. 2011; 68(4):889-96. DOI: 10.1007/s00280-011-1567-2. View

Ko Y, Small E, Kabbinavar F, Chachoua A, Taneja S, Reese D . A multi-institutional phase ii study of SU101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer. Clin Cancer Res. 2001; 7(4):800-5. View

Fossa S, Nilssen Y, Kvale R, Hernes E, Axcrona K, Moller B . Treatment and 5-year survival in patients with nonmetastatic prostate cancer: the Norwegian experience. Urology. 2013; 83(1):146-52. DOI: 10.1016/j.urology.2013.08.081. View

Armstrong A, Halabi S, Healy P, Lee W, Koontz B, Moul J . A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy. Prostate Cancer Prostatic Dis. 2016; 19(1):100-6. DOI: 10.1038/pcan.2015.59. View

10.

Andersen S, Richardsen E, Nordby Y, Ness N, Storkersen O, Al-Shibli K . Disease-specific outcomes of radical prostatectomies in Northern Norway; a case for the impact of perineural infiltration and postoperative PSA-doubling time. BMC Urol. 2014; 14:49. PMC: 4067377. DOI: 10.1186/1471-2490-14-49. View

11.

Donnem T, Hu J, Ferguson M, Adighibe O, Snell C, Harris A . Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment?. Cancer Med. 2013; 2(4):427-36. PMC: 3799277. DOI: 10.1002/cam4.105. View

12.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

13.

Chu J, Ge F, Zhang B, Wang Y, Silvestris N, Liu L . Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma. J Exp Clin Cancer Res. 2013; 32:16. PMC: 3623756. DOI: 10.1186/1756-9966-32-16. View

14.

Ustach C, Huang W, Conley-LaComb M, Lin C, Che M, Abrams J . A novel signaling axis of matriptase/PDGF-D/ß-PDGFR in human prostate cancer. Cancer Res. 2010; 70(23):9631-40. PMC: 3058856. DOI: 10.1158/0008-5472.CAN-10-0511. View

15.

Conley-LaComb M, Huang W, Wang S, Shi D, Jung Y, Najy A . PTEN regulates PDGF ligand switch for β-PDGFR signaling in prostate cancer. Am J Pathol. 2012; 180(3):1017-1027. PMC: 3349886. DOI: 10.1016/j.ajpath.2011.11.021. View

16.

Epstein J . An update of the Gleason grading system. J Urol. 2009; 183(2):433-40. DOI: 10.1016/j.juro.2009.10.046. View

17.

Paulsson J, Ehnman M, Ostman A . PDGF receptors in tumor biology: prognostic and predictive potential. Future Oncol. 2014; 10(9):1695-708. DOI: 10.2217/fon.14.83. View

18.

Matei D, Kelich S, Cao L, Menning N, Emerson R, Rao J . PDGF BB induces VEGF secretion in ovarian cancer. Cancer Biol Ther. 2007; 6(12):1951-9. DOI: 10.4161/cbt.6.12.4976. View

19.

Chen P, Chen X, He X . Platelet-derived growth factors and their receptors: structural and functional perspectives. Biochim Biophys Acta. 2012; 1834(10):2176-86. PMC: 3612563. DOI: 10.1016/j.bbapap.2012.10.015. View

20.

Sethi S, Macoska J, Chen W, Sarkar F . Molecular signature of epithelial-mesenchymal transition (EMT) in human prostate cancer bone metastasis. Am J Transl Res. 2010; 3(1):90-9. PMC: 2981429. View